Wave Life Sciences, Inc. — Form 10-Q
Filed October 27, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
On August 7, 2026, Wave Life Sciences Ltd. (Singapore) transferred its Pfizer Ventures investment agreement to newly incorporated Wave Life Sciences, Inc. (Delaware), following a scheme of arrangement that made Delaware Wave the parent company. Pfizer's 1,875,000 ordinary shares were exchanged 1:1 for Wave-Delaware common stock. The assignment required Pfizer's consent and amendment to the original May 5, 2016 Share Purchase Agreement; no economic terms or valuations were altered.
Why this rating
Corporate redomiciling is routine restructuring; no material economic change, capital raise, or operational impact. Pfizer stake (~$220M at current valuation) remains unchanged in substance. Administrative.
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.